Cheelcare Has a Record Month of Sales and Celebrates Milestone of 2,000 Companions Sold
Markham, Ontario--(Newsfile Corp. - December 8, 2025) - Cheelcare (TSXV: CHER), a Canadian innovator in advanced mobility solutions, is proud to announce that the Company has reached a major commercial milestone with the sale of its 2,000th Companion, coinciding with a record month of production and sales. This reflects accelerating market adoption and growing demand for innovative mobility solutions. The Companion is Cheelcare's flagship power-assist device, purpose-built to augment ma
2025-12-08 7:00 AM EST | Cheelcare Inc.
Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, is pleased to announce that it has successfully closed the final tranche of its non-brokered private placement (the "Offering"). In this final tranche, the Company issued 3,050,000 units ("Units") at a price of $0.05 per Unit, for gross proceeds of $152,500, bringing the to
2025-12-05 5:02 PM EST | Predictmedix AI Inc.
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company based in the Netherlands
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-05 5:00 PM EST | TempraMed Technologies Ltd
Restart Life Sciences Announces Closing First Tranche of Financing
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025, the Company has closed the first tranche of its non-brokered private placement for total gross proceeds of CDN$500,000 (the "Placement"). Pursuant to the Placement, the Company has allotted and issued 5,000,000 units (the "Units") at a p
Technology, Biotechnology, Health
2025-12-05 5:00 PM EST | Restart Life Sciences Corp.
Correction to MyndTec Inc. Press Release Issued December 3, 2025 Regarding Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 5, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), announced today a correction to its press release titled "MyndTec Inc. Completes Eighth Tranche of Non-Brokered Private Placement" issued on December 3, 2025 (the "Initial Press Release"). The Initial Press Release incorrectly stated the number of units issued under the eighth tranche of the private placement Offering as 351,475 Units, the aggregate
Technology, Healthcare and Hospitals, Health
2025-12-05 4:30 PM EST | MyndTec Inc.
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In this senior clinical role, Ms. Harding will oversee: On-boarding of all new patients entering Hemostemix treatment programs;
Biotechnology, Pharmaceuticals, Health
2025-12-04 9:10 AM EST | Hemostemix Inc.
Rejuvenate Muscle Health Wins Prestigious "Best Drink" Award at 2025 ECRM Vitamin, Weight Management & Sports Nutrition Session
Burlington, Ontario--(Newsfile Corp. - December 4, 2025) - Promino Nutritional Sciences Inc. (CSE: MUS
Food / Beverages, Sports, Health
2025-12-04 7:00 AM EST | Promino Nutritional Sciences, Inc.
PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Australian Patent Office has granted Australian Patent No. AU2020212659, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This patent represents a significant milestone in the development and protection of PreveCeutical's proprie
Biotechnology, Pharmaceuticals, Health
2025-12-04 7:00 AM EST | PreveCeutical Medical Inc.
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board ("SAB"), composed of Rob Leanna, Danny Chui, and Brendan Hussey. Defence
Biotechnology, Pharmaceuticals, Health
2025-12-04 3:15 AM EST | Defence Therapeutics Inc.
MyndTec Inc. Completes Eighth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 3, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the eighth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The eighth tranche of the private placement consists of 351,475 Units of the Company (the "Units") at a price of $0.20
Technology, Healthcare and Hospitals, Health
2025-12-03 5:00 PM EST | MyndTec Inc.
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, wound care, diabetic limb salvage, and regenerative therapeutics gather to present cutting-edge advancements. Hemostemix will highlig
Biotechnology, Pharmaceuticals, Health
2025-12-03 2:05 PM EST | Hemostemix Inc.
Microbiome Labs Launches DigestMate, a 2-in-1 Digestive Enzyme and Probiotic Formula
Franklinton, North Carolina--(Newsfile Corp. - December 3, 2025) - Microbiome Labs, a leader in microbiome-based solutions, today announced the launch of DigestMate™, a 2-in-1 digestive enzyme and probiotic formula. Digestive health challenges are on the rise in America, impacting millions of lives and driving demand for innovative solutions. According to recent data from the Centers for Disease Control and Prevention (CDC) and the National Institute of Diabetes and Digestive and
2025-12-03 11:44 AM EST | Microbiome Labs
BioHarvest Sciences Announces Launch of VINIA Blood Flow Hydration Product
British Columbia and Rehovot, Israel--(Newsfile Corp. - December 3, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the U.S. launch of VINIA Blood Flow Hydration™, the first hydration solution powered by the blood flow
Biotechnology, Pharmaceuticals, Health
2025-12-03 7:30 AM EST | BioHarvest Sciences Inc.
Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway
Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo and the second study reaching 168% relative improvement to placebo Positive safety profile demonstrated
Healthcare and Hospitals, Health
2025-12-03 1:12 AM EST | Cosmo Pharmaceuticals N.V.
TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance One of many distribution agreements in pipeline for Europe as part of TempraMed's def
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-02 5:00 PM EST | TempraMed Technologies Ltd
DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx(TM) Red Eye Diagnostic Test
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, is pleased to announce a collaboration with AlyaTec, a globally renowned Contract Research Organization (CRO), specializing in allergy and environmental diseases, to initiate a clinical study of TeaRx™ Red Eye in order to advance the global commercialization of
2025-12-02 5:00 PM EST | DiagnosTear Technologies Inc.
Promino Resumes Trading and Achieves Record Sales Growth Through October 2025
Burlington, Ontario--(Newsfile Corp. - December 2, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company") is pleased to announce the resumption of trading on the Canadian Securities Exchange effective today. The trading halt, in effect since May 8, 2025, has been lifted following the filing of Promino's 2024 audited financial statements, Management's Discussion and Analysis and related officer certifications, as well as all current interi
Food / Beverages, Sports, Health
2025-12-02 10:35 AM EST | Promino Nutritional Sciences, Inc.
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 500 delegates expected, DFCon gathers the widest spectrum of professionals shaping the future of diabetic limb salvage: podiatrists, vascular surgeo
Biotechnology, Pharmaceuticals, Health
2025-12-02 9:10 AM EST | Hemostemix Inc.
St. Baldrick's Launches Giving Tuesday Campaign to Raise $75,000 for Childhood Cancer Research
Los Angeles, California--(Newsfile Corp. - December 2, 2025) - This Giving Tuesday the St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants in the U.S., invites communities across the country to join the fight against childhood cancer. With a goal of raising $75,000, the campaign will support pioneering research that gives kids battling cancer a chance at a healthy, hopeful life — because
2025-12-02 9:00 AM EST | St. Baldrick's Foundation
Functional Brands Inc. Announces P2i(TM) by Kirkman(R) as the World's First Prenatal Supplement to Fully Align with FIGO's Transparency Standards - and the First to Comply with California's New SB 646 QR-Code Disclosure Law
Lake Oswego, Oregon--(Newsfile Corp. - December 2, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced that P2i™ by Kirkman® Prenatal Multivitamin & Multimineral is the first prenatal supplement in the world to align its testing and transparency practices with the International Federation of Gynecology and Obstetrics (FIGO) position statement on toxic chemicals and environmental contaminants in prenatal vitami
Household / Consumer / Cosmetics, Health
2025-12-02 8:00 AM EST | Functional Brands Inc.